-3.02%
-9.95%
-18.10%
0.52%
73.35%
55.23%
293.88%
AI Spotlight on MNKD
Company Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States.It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes.It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism.
The company has a license and collaboration agreement with United Therapeutics Corporation.It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions.MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Market Data
| Last Price | 5.79 |
| Change Percentage | -3.02% |
| Open | 5.97 |
| Previous Close | 5.97 |
| Market Cap ( Millions) | 1597 |
| Volume | 2885893 |
| Year High | 7.63 |
| Year Low | 3.17 |
| M A 50 | 6.48 |
| M A 200 | 5.77 |
Financial Ratios
| FCF Yield | 1.79% |
| Dividend Yield | 0.00% |
| ROE | -9.46% |
| Debt / Equity | -114.46% |
| Net Debt / EBIDTA | 298.11% |
| Price To Book | -7.58 |
| Price Earnings Ratio | 73.83 |
| Price To FCF | 55.79 |
| Price To sales | 5.98 |
| EV / EBITDA | 29.74 |
News
- Jan -06 - MannKind Expands Executive Leadership Team
- Dec -17 - MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets
- Dec -16 - MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
- Dec -11 - CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
- Nov -08 - MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call Transcript
- Nov -08 - MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say
- Nov -07 - MannKind (MNKD) Matches Q3 Earnings Estimates
- Nov -07 - MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
- Nov -05 - MannKind to Present at 2024 UBS Healthcare Conference
- Nov -04 - MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
- Oct -31 - First Site Initiated in Australia for MannKind's Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
- Oct -07 - Why MannKind (MNKD) Could Beat Earnings Estimates Again
- Oct -04 - MannKind (MNKD) Just Overtook the 20-Day Moving Average
- Oct -03 - MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion
- Sep -30 - More Adults With Type 1 Diabetes Achieved A1C Goal (
- Sep -18 - MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
- Sep -10 - MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
- Aug -27 - MannKind to Present at Upcoming Conferences
- Aug -09 - Is MannKind (MNKD) Stock Outpacing Its Medical Peers This Year?
- Aug -07 - MannKind Corporation (MNKD) Q2 2024 Earnings Call Transcript
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Innovative Therapeutic Products and Devices
Expected Growth : 8.5 %
What the company do ?
MannKind Corporation's innovative therapeutic products and devices focus on inhaled insulin, Afrezza, and other pulmonary arterial hypertension treatments, improving patient outcomes.
Why we expect these perspectives ?
MannKind Corporation's 8.5% growth in Innovative Therapeutic Products and Devices is driven by increasing adoption of its inhalable insulin Afrezza, strong demand for its pulmonary arterial hypertension treatment Tyvaso, and expansion into new markets. Additionally, strategic partnerships and investments in R&D are expected to fuel future growth.
Mannkind Corporation Products
| Product Range | What is it ? |
|---|---|
| Afrezza | Afrezza is a rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. |
| Dreamboat | Dreamboat is a dry powder inhaler device designed to deliver Afrezza, providing a convenient and discreet way to take inhaled insulin. |
| Technosphere | Technosphere is a proprietary technology platform used to develop and manufacture inhaled therapeutic products, including Afrezza. |
MannKind Corporation's Porter Forces
Threat Of Substitutes
MannKind Corporation's Afrezza, an inhaled insulin, faces competition from traditional insulin injections and other diabetes treatments, but its unique delivery method and convenience provide some protection from substitutes.
Bargaining Power Of Customers
As a pharmaceutical company, MannKind Corporation's customers are primarily healthcare providers and patients, who have limited bargaining power due to the specialized nature of the company's products.
Bargaining Power Of Suppliers
MannKind Corporation relies on a limited number of suppliers for the production of Afrezza, which gives these suppliers some bargaining power, but the company's patents and proprietary technology mitigate this risk.
Threat Of New Entrants
The pharmaceutical industry has high barriers to entry, including significant research and development costs, regulatory hurdles, and patent protections, making it difficult for new entrants to compete with MannKind Corporation.
Intensity Of Rivalry
The diabetes treatment market is highly competitive, with many established players, including Eli Lilly, Novo Nordisk, and Sanofi, which creates a high level of rivalry for MannKind Corporation's Afrezza.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 748.37% |
| Debt Cost | 5.72% |
| Equity Weight | -648.37% |
| Equity Cost | 10.63% |
| WACC | -26.13% |
| Leverage | -115.42% |
MannKind Corporation : Quality Control
MannKind Corporation passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| OABI | OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies … |
| SYRS | Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates … |
| XERS | Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for … |
| DNTH | Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that … |
| KYMR | Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Xeris Biopharma
A-Score
1-Year Total Return ->
🥈
MannKind
A-Score
1-Year Total Return ->
🥉
Dianthus Therapeutics
A-Score
1-Year Total Return ->
4
Kymera Therapeutics
A-Score
1-Year Total Return ->
5
OmniAb
A-Score
1-Year Total Return ->
6
